参考文献
(在框内滑动手指即可浏览)
[1] Morris LG, Sikora AG, Tosteson TD, et al. The increasing incidence of thyroid cancer: the influence of access to care[J]. Thyroid, 2013, 23(7):885-891.
[2] Siegel RL, Miller KD and Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[3] 中国医师协会外科医师分会甲状腺外科医师委员会,中国研究型医院学会甲状腺疾病专业委员会. 分化型甲状腺癌术后管理中国专家共识(2020 版)[J]. 中国实用外科杂志,2020,40(9):1021-1028.
[4] 田文,郗洪庆. 分化型甲状腺癌外科治疗进展及展望[J]. 中国实用外科杂志,2020,40(1):78-82.
[5] Lang BHH, Wong CKH, Yu HW, et al. Postoperative nomogram for predicting disease-specific death and recurrence in papillary thyroid carcinoma[J]. Head Neck, 2016, 38(suppl1):E1256-E1263.
[6] 张浩. 分化型甲状腺癌术后复发的处理策略[J]. 中华普外科手术学杂志(电子版), 2016, 10(5):373-375.
[7] 中国临床肿瘤学会指南工作委员会甲状腺癌专家委员会. 中国临床肿瘤学会(CSCO)持续/复发及转移性分化型甲状腺癌诊疗指南-2019[J]. 肿瘤预防与治疗, 2019, 32(12):1051-1080.
[8] 中国医师协会甲状腺肿瘤消融治疗技术专家组,中国抗癌协会甲状腺癌专业委员会,中国医师协会介入医师分会超声介入专业委员会,等. 甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗专家共识(2018版)[J]. 中国肿瘤, 2018, 27(10):768-773.
[9] Tufano RP, Clayman G, Heller KS, et al. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance[J]. Thyroid, 2015, 25(1):15-27.
[10] Scharpf J, Tuttle M, Wong R, et al. Comprehensive management of recurrent thyroid cancer: An American Head and Neck Society consensus statement: AHNS consensus statement[J]. Head Neck, 2016, 38(12):1862-1869.
[11] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1):1-133.
[12] Clayman GL and Steward DL. Management of Persistent or Recurrent Structural Neck Disease in Differentiated Thyroid Carcinoma: Point and Counterpoint[J]. JAMA Otolaryngol Head Neck Surg, 2016, 142(8):789-791.
[13] Zerdoud S, Giraudet AL, Leboulleux S, et al. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery[J]. Ann Endocrinol (Paris), 2017, 78(3):162-175.
[14] Pacini F, Basolo F, Bellantone R, et al. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies[J]. J Endocrinol Invest, 2018, 41(7):849-876.
[15] Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(12):1856-1883.
[16] Mazzaferri EL,Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5):418-428.
[17] Mazzaferri EL,Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer[J]. J Clin Endocrinol Metab, 2001, 86(4):1447-1463.
[18] Durante C, Montesano T, Torlontano M, et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance[J]. J Clin Endocrinol Metab, 2013, 98(2):636-642.
[19] Ito Y, Higashiyama T, Takamura Y, et al. Prognosis of patients with papillary thyroid carcinoma showing postoperative recurrence to the central neck[J]. World J Surg, 2011, 35(4):767-772.
[20] Coburn M, Teates D and Wanebo HJ. Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131)[J]. Ann Surg, 1994, 219(6):587-593; discussion 593-595.
[21] Wang LY, Migliacci JC, Tuttle RM, et al. Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer[J]. Clin Endocrinol, 2017, 87(5):566-571.
[22] Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension[J]. Thyroid, 2012, 22(11):1144-1152.
[23] Young S, Harari A, Smooke-Praw S, et al. Effect of reoperation on outcomes in papillary thyroid cancer[J]. Surgery, 2013, 154(6):1354-1361; discussion 1361-1362.
[24] Yim JH, Kim WB, Kim EY, et al. The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation[J]. J Clin Endocrinol Metab, 2011, 96(7):2049-2056.
[25] Al-Saif O, Farrar WB, Bloomston M, et al. Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2010, 95(5):2187-2194.
[26] Onuma AE, Beal EW, Nabhan F, et al. Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer: 13-year follow-up[J]. Ann Surg Oncol, 2019, 26(6):1737-1743.
[27] Kim JH, Baek JH, Lim HK, et al. 2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology[J]. Korean J Radiol, 2018, 19(4):632-655.
[28] Clayman GL, Agarwal G, Edeiken BS, et al. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma[J]. Thyroid, 2011, 21(12):1309-1316.
[29] Urken ML, Milas M, Randolph GW, et al. Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative[J]. Head Neck, 2015, 37(4):605-614.
[30] Lang BH, Shek TW, Chan AO, et al. Significance of size of persistent/recurrent central nodal disease on surgical morbidity and response to therapy in reoperative neck dissection for papillary thyroid carcinoma[J]. Thyroid, 2017, 27(1):67-73.
[31] McNamara WF, Wang LY, Palmer FL, et al. Pattern of neck recurrence after lateral neck dissection for cervical metastases in papillary thyroid cancer[J]. Surgery, 2016, 159(6):1565-1571.
[32] Ahmadi N, Grewal A and Davidson BJ. Patterns of cervical lymph node metastases in primary and recurrent papillary thyroid cancer[J]. J Oncol, 2011, 2011:735678.
[33] Chéreau N, Buffet C, Trésallet C, et al. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management[J]. Surgery, 2016, 159(3):755-762.
[34] Chinn SB, Zafereo ME, Waguespack SG, et al. Long-term outcomes of lateral neck dissection in patients with recurrent or persistent well-differentiated thyroid cancer[J]. Thyroid, 2017, 27(10):1291-1299.
[35] Hung ML, Wu JX, Li N, et al. Association of radioactive iodine administration after reoperation with outcomes among patients with recurrent or persistent papillary thyroid cancer[J]. JAMA Surg, 2018, 153(12):1098-1104.
[36] Yim JH, Kim WB, Kim EY, et al. Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation[J]. J Clin Endocrinol Metab, 2011, 96(12):3695-3700.
[37] Bouvet C, Barres B, Kwiatkowski F, et al. Re-treatment with adjuvant radioactive iodine does not improve recurrence-free survival of patients with differentiated thyroid cancer[J]. Front Endocrinol (Lausanne), 2019, 10:671.
[38] Lassmann M, Reiners C,Luster M. Dosimetry and thyroid cancer: the individual dosage of radioiodine[J]. Endocr Relat Cancer, 2010, 17(3):R161-172.
[39] Piccardo A, Puntoni M, Bottoni G, et al. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy[J]. Eur J Nucl Med Mol Imaging, 2017, 44(6):926-934.
[40] Weslley Rosario P, Franco Mourão G and Regina Calsolari M. Role of adjuvant therapy with radioactive iodine in patients with elevated serum thyroglobulin after neck reoperation due to recurrent papillary thyroid cancer: a monoinstitutional comparative study[J]. Endocrine, 2020, 68(1):144-150.
[41] Hirsch D, Gorshtein A, Robenshtok E, et al. Second radioiodine treatment: Limited benefit for differentiated thyroid cancer with locoregional persistent disease[J]. J Clin Endocrinol Metab, 2018, 103(2):469-476.
[42] Sippel RS,Chen H. Controversies in the surgical management of newly diagnosed and recurrent/residual thyroid cancer[J]. Thyroid, 2009, 19(12):1373-1380.
[43] Choi Y, Jung SL, Bae J-S, et al. Comparison of efficacy and complications between radiofrequency ablation and repeat surgery in the treatment of locally recurrent thyroid cancers: a single-center propensity score matching study[J]. Int J Hyperthermia, 2019, 36(1):359-367.
[44] Chung SR, Baek JH, Choi YJ, et al. Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer[J]. Eur Radiol, 2019, 29(9):4897-4903.
[45] Chung SR, Baek JH, Choi YJ, et al. Efficacy of radiofrequency ablation for recurrent thyroid cancer invading the airways[J]. Eur Radiol, 2021, 31(4):2153-2160.
[46] Kim C, Lee JH, Choi YJ, et al. Complications encountered in ultrasonography-guided radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers[J]. Eur Radiol, 2017, 27(8):3128-3137.
[47] Chung SR, Suh CH, Baek JH, et al. Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: a systematic review and meta-analysis[J]. Int J Hyperthermia, 2017, 33(8):920-930.
[48] Ha EJ, Baek JH and Lee JH. Ultrasonography-Based Thyroidal and Perithyroidal Anatomy and Its Clinical Significance[J]. Korean J Radiol, 2015, 16(4):749-766.
[49] Baek JH, Lee JH, Sung JY, et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study[J]. Radiology, 2012, 262(1):335-342.
[50] Zhou W, Zhang L, Zhan W, et al. Percutaneous laser ablation for treatment of locally recurrent papillary thyroid carcinoma <15 mm[J]. Clin Radiol, 2016, 71(12):1233-1239.
[51] Ha EJ, Baek JH, Lee JH, et al. Clinical significance of vagus nerve variation in radiofrequency ablation of thyroid nodules[J]. Eur Radiol, 2011, 21(10):2151-2157.